CompletedNot Applicable

Observational Study of Vision Improvement in Late Stage Dry AMD Patients

Canada17 participantsStarted 2020-08-14

Plain-language summary

The purpose of this study is to assess the vision improvement achieved by patients with late stage dry age-related macular degeneration who received corneal treatments by a low vision aid device.

Who can participate

Age range50 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. \- Male or female
✓. \- Any race
✓. \- Patient is at least 50 years old
✓. \- Patient has diagnosed late stage dry age-related macular degeneration in one or both eyes.
✓. \- Treated eyes were pseudophakic at the time of treatment.
✓. \- Patient had moderate to severe baseline vision impairment with best spectacle-corrected distance visual acuity (CDVA) of 20/63 or worse (decimal = 0.317 or less; logMAR greater than or equal to 0.50) in the treated eye(s).
✓. \- Patient CDVA records are available at baseline and at 12 month post-treatment.

Exclusion criteria

✕. \- Corneal disease or disorder in either eye.
✕. \- Increased intraocular pressure (above 20 mm Hg), glaucoma or history of glaucoma.
✕. \- Presence or history of any other condition or finding that, in the opinion of the investigator, makes the patient unsuitable for retrospective observational study.

What they're measuring

CDVA

Timeframe: 12 months

Trial details

NCT IDNCT04349254

SponsorOptimal Acuity Corporation

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2020-12-31

View on ClinicalTrials.gov More Dry Age-related Macular Degeneration trials